Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study
© The Author(s) 2010
Received: 26 May 2010
Accepted: 23 November 2010
Published: 23 November 2010
Antigen desensitization through oral tolerance is becoming an increasingly attractive treatment option for allergic diseases. However, the mechanism(s) by which tolerization is achieved remain poorly defined. In this study we endeavored to induce oral tolerance to cockroach allergen (CRA: a complex mixture of insect components) in order to ameliorate asthma-like, allergic pulmonary inflammation.
We compared the pulmonary inflammation of mice which had received four CRA feedings prior to intratracheal allergen sensitization and challenge to mice fed PBS on the same time course. Respiratory parameters were assessed by whole body unrestrained plethysmography and mechanical ventilation with forced oscillation. Bronchoalveolar lavage fluid (BAL) and lung homogenate (LH) were assessed for cytokines and chemokines by ELISA. BAL inflammatory cells were also collected and examined by light microscopy.
CRA feeding prior to allergen sensitization and challenge led to a significant improvement in respiratory health. Airways hyperreactivity measured indirectly via enhanced pause (Penh) was meaningfully reduced in the CRA-fed mice compared to the PBS fed mice (2.3 ± 0.4 vs 3.9 ± 0.6; p = 0.03). Directly measured airways resistance confirmed this trend when comparing the CRA-fed to the PBS-fed animals (2.97 ± 0.98 vs 4.95 ± 1.41). This effect was not due to reduced traditional inflammatory cell chemotactic factors, Th2 or other cytokines and chemokines. The mechanism of improved respiratory health in the tolerized mice was due to significantly reduced eosinophil numbers in the bronchoalveolar lavage fluid (43300 ± 11445 vs 158786 ± 38908; p = 0.007) and eosinophil specific peroxidase activity in the lung homogenate (0.59 ± 0.13 vs 1.19 ± 0.19; p = 0.017). The decreased eosinophilia was likely the result of increased IL-10 in the lung homogenate of the tolerized mice (6320 ± 354 ng/mL vs 5190 ± 404 ng/mL, p = 0.02).
Our results show that oral tolerization to CRA can improve the respiratory health of experimental mice in a CRA-induced model of asthma-like pulmonary inflammation by reducing pulmonary eosinophilia.
Asthma is a significant chronic health problem in the U.S. and other developed nations. It accounts for millions of hospitalizations and thousands of deaths per year. The incidence of this burdensome ailment has increased by 50% every ten years raising the prevalence in the U.S. to 26.7 million in 1997 [1, 2].
A significant disparity in new asthma diagnoses has been noted between urban and suburban/rural children. Urban children suffer a significantly higher incidence of asthma than their non city-dwelling counterparts . This effect has been attributed to differences in exposure to sensitizing allergens present in the environment. Namely, it is theorized that an allergen(s) present at higher concentration, or in a unique combination in urban environments is the principal aggravating factor. Suspected allergens include feline, canine, murine, dust mite and cockroach allergen and pollutants such as diesel particulates.
A landmark paper published in 1997 identified a link between asthma incidence in urban children and antigens derived from the ubiquitous pest Blattella germanica, the German cockroach . This link was further investigated in 1998 by the development of the first cockroach allergen induced model of asthma . Publications from this lab have shown that aqueous house dust extract from the kitchens of severely asthmatic, urban children can induce allergic asthma-like symptoms in mice. Moreover, the most potent and abundant allergens identified in the dust extract were proteins of the German cockroach . Thus, the study of cockroach allergen as an inducer of asthma in mice and humans is a rational first step in untangling the complex web of environmental exposure and allergic asthma.
Despite the alarming increase in prevalence and incidence of asthma in recent times, treatments have evolved slowly. Current standards of care include a long lasting anti-inflammatory agent such as an inhaled glucocorticoid or long acting β2 adrenergic agonist, combined with a short acting β2 agonist rescue inhaler and or epinephrine injections. Other effective agents include anti-IgE monoclonal antibodies, leukotriene receptor antagonists, mast cell degranulation inhibitors, antihistamines and cholinergic antagonists [1, 6, 7]. These treatments focus on alleviating the symptoms of the disease rather than addressing the cause. Specifically, they manipulate events occurring downstream of the aggravating stimulus to diminish certain aspects of the response. While these drugs are very effective at decreasing exacerbations and halting attacks, they tend to lose effectiveness over time. Asthma progresses because chronic, inflammation-induced lung remodeling coupled with drug desensitization, allow the disease to become more severe and recalcitrant to treatment over time.
Allergen desensitization is thus a highly attractive option for the treatment of allergic-type inflammatory diseases. This form of treatment has a significant advantage over standard therapeutic agents in that it addresses the fundamental cause of asthma rather than modifying downstream mediators. In addition allergen desensitization has the advantage of being tailored to the individual patient. A skin hypersensitivity panel can be performed for a wide array of potential allergens in order to identify the causative agent(s). Thus, the desensitization regimen can be narrowly focused on the most likely causative allergens, offering symptomatic relief based on rational and specific treatment targeted to the inciting allergens(s).
Current desensitization procedures deliver increasing titers of the putative allergen subcutaneously over a period of weeks. The patient must travel to their physician's office and remain in the clinic for 30 minutes after the injection in case a life-threatening reaction occurs. In addition, the administering health professional must be specially trained and have the capacity to treat severe anaphylaxis [8, 9]. These factors make current desensitization procedures relatively costly and inconvenient for both the patient and the care provider.
Sublingual/oral allergen desensitization is starting to gain wider interest and acceptance[10, 11] with significant advantages over subcutaneous desensitization. Chief among these is the lower potential for anaphylaxis. The patient is monitored for severe reactions only after the first dose; subsequently, he/she can self-administer treatment in their own home. This vastly increases compliance as there is very little disruption of the patient's daily schedule. This is especially true for asthmatic children in whom compliance is a significant issue. Therefore, oral desensitization is an ideal candidate for the treatment of allergic type asthma.
Although oral tolerance is gaining wider acceptance, the mechanism of how this occurs has not been determined. We designed studies to examine whether oral tolerance would effectively relieve asthma-like pulmonary inflammation in response to cockroach allergens, and determine the mechanism(s) of why oral tolerance is effective.
We used exclusively female HSD-ICR mice at 18-20 grams. (Harlan Sprague Dawley Inc., Frederick, MD). All data represent the combination of 3 replicates except for direct airways resistance measurement which is the combination of 2 replicates. All experiments were reviewed and approved by the Boston University School of Medicine Institutional Animal Care and Use Committee.
Oral exposure to allergens was performed by gavage. Briefly, a solution containing 16 ug of combined Blag1 and Blag2 was prepared in 100 ul of PBS. Mice were lightly anesthetized with isoflurane and the solution delivered directly to the stomach by means of a metal gavage needle. Control mice received 100 ul of PBS by the same method. Feeding was performed daily for 4 days. The mice were given a 3 day rest period before the allergen sensitization protocol. For allergen specificity ovalbumin (OVA) was given on the same schedule and volume as those described above. The OVA solution was adjusted to provide the same total protein concentration as the CRA mixture, 7.35 mg/mL. Following the OVA tolerization period, the mice received CRA immunization and 2 CRA challenges along the same schedule as the CRA tolerized animals.
Cockroach antigen (CRA) was purchased from Greer Laboratories (Lenoir, NC) as a lyophilized whole body extract of the German cockroach Blattella germanica. The CRA was reconstituted in sterile PBS and the concentration of components Blag1 and Blag2 were assayed by ELISA. The concentration of the solution was adjusted so that 50 ul contained 8 ug of combined Blag1 and Blag2. The immunization (day 0) and 2 challenges (days 14 and 21) were delivered intratracheally by direct pharyngeal delivery which is subsequently inhaled . Briefly, the mouse was suspended by its front incisors on an incline board, its tongue was gently pulled forward and the CRA solution was placed at the back of the pharynx in two 25 ul aliquots for aspiration. The immunization dose was a 1:2 of the stock solution and the challenges were a 1:4 containing 4 ug and 2 ug combined Blag1 and Blag2 respectively. The naïve mice received no CRA challenges. The 0 Hr mice were administered 2 intratracheal challenges of CRA and were assayed and sacrificed at the time they would have received their final allergen challenge, i.e. they did not receive the third challenge. The 1.5 Hr and 24 Hr mice were given the full set of 3 challenges and were assayed and sacrificed at 1.5 and 24 hours post final challenge respectively.
Mice were placed in unrestrained whole body plethysmograph chambers at the same time of day and exposed to a 2 minute aerosolization of PBS, 25 mg/mL or 50 mg/mL methacholine followed by a 5 minute recording period [13, 14]. The mice were first allowed to explore the chambers with normal grooming behavior indicating that the mice had become acclimated. Direct resistance measurements were made on a flexivent instrument (ScireQ, Montreal, QC, Canada). Briefly, mice were anesthetized with pentobarbital, and the trachea was directly cannulated through a small incision. The mice were placed on the mechanical ventilator and then paralyzed with pancuronium bromide. A nebulizer attached to the instrument delivered PBS, and methacholine challenges at 25 and 50 mg/mL while airways resistance was measured.
Sacrifice and Data Collection
The mice were anesthetized with intrperitoneal ketamine/xylazine and then sacrificed by exsanguination and cervical dislocation. The trachea was opened and cannulated with a length of flexible tubing and the lungs were lavaged with 2 mL of warm HBSS in 250 ul aliquots. The left lung was removed and fixed in 70% ethanol for histology. The right lung was placed into ice cold Complete Protease Inhibitor Cocktail (Roche Chemicals, Switzerland). The right lungs are then homogenized, the homogenate centrifuged at 10,000 G for 15 minutes and the supernatant removed for cytokine analysis. The cellular components of the whole lung homogenate were then resuspended in 0.5% cetyltrimethylammonium chloride (CTAC) and sonicated to release the contents of the eosinophilic granules. The supernatant of this mixture was collected and assessed for peroxidase activity (EPO). The lavage fluid was centrifuged at 600 G for 5 minutes and the supernatant was removed. The cell pellet was resuspended in 200 ul of RPMI, the red cells lysed and counted on Coulter particle counter (Beckman Coulter, Fullerton CA). The cells were then adhered to a slide and counted at 100 × magnification. The absolute cell counts per BAL sample were calculated for total white cells, neutrophils, macrophages, eosinophils and lymphocytes. Blood samples were taken from each mouse at exsanguination for cell counting on a Hemavet (Drew Scientific, Dallas, TX). Cell counts were expressed as the absolute number of a particular cell per 20 ul blood sample.
Cytokine and chemokine analysis
Cytokines and chemokines were measured using sandwich ELISA . Briefly, Nunc (Rochester, NY) plates were coated overnight at 4C with anti-cytokine antibodies, the plates were blocked, samples were incubated on plates for 2 hours at room temperature, a biotinylated secondary antibody was used to detect captured cytokines and chemokines following incubation with strepavidin conjugated horse radish peroxidase (SA-HRP) and a colorimetric reaction. BAL samples were diluted 1:2, lung homogenate samples were diluted 1:5 and standards contained an equal concentration of pooled naïve lung homogenate. Plates were read with a PowerWaveX plate reader (Bio-Tek Instruments, Hopkinton, MA).
Statistical comparisons were performed by two-tailed t-test in Graphpad Prism 4.0 (La Jolla, CA). Power analysis was performed using freeware tools on http://www.biomath.info/ The coefficient of variance was calculated as the ratio of the standard deviation and the mean of each data set or CV = standard deviation/mean.
Initially, we examined the respiratory parameters in CRA-fed (tolerized) and PBS-fed mice following allergen sensitization and 2 challenges. We compared respiratory data in response to 50 mg/mL of methacholine (Mch) because this dose provided a maximal response. The first parameter we analyzed was enhanced pause (Penh). Penh is a dimensionless composite parameter which can be used to screen experimental animals for airways hyperreactivity to Mch and obstruction [16–18]. Changes in Penh can be caused by any factor which alters the caliber of conducting airways including inflammation, smooth muscle constriction and luminal obstruction with mucus.
Next we examined a host of other respiratory parameters which we have found to be correlated with the respiratory health of mice in our model of asthma. First we examined minute ventilation (MV). The minute ventilation of the CRA fed mice was significantly higher than that of the PBS fed animals (Figure 1B). Maintenance of an elevated MV in times pulmonary distress is associated with superior respiratory health [22–24]. Namely, when lung disease is more severe, acute exacerbations cause involuntary decreases in MV. To determine the etiology of this difference we examined the components of MV, respiratory rate (RR) and tidal volume (TV). Respiratory rate was significantly higher in the CRA fed mice but there was no difference in TV (Figure 1C, D). This indicates that the low MV in the PBS fed mice was due principally to a depressed RR.
Parameters measured in CRA fed and PBS fed mice 4 hours after final challenge. BAL and LH cytokines assessed by sandwich ELISA and given in pg/mL.
77.86 ± 7.76
96.3 ± 7.41
7870 ± 2287
6496 ± 983.8
4.39 ± 0.77
3.25 ± 0.42
173.3 ± 40.6
214.3 ± 47.9
8500 ± 1243
8340 ± 1651
45.21 ± 5.47
54.05 ± 8.92
45.67 ± 8.3
59.95 ± 14.8
2951 ± 297.8
2981 ± 275.8
0.34 ± 0.12
0.54 ± 0.19
34.34 ± 3.48
41.96 ± 3.38
1461 ± 216.7
1341 ± 198.8
6.8E5 ± 7.7E4
6.3E5 ± 7.7E4
69.06 ± 4.58
72.27 ± 6.13
4739 ± 650.7
4706 ± 656.8
1.3E5 ± 1.4E4
1.1E5 ± 1.6E4
816.7 ± 142.9
813.6 ± 89.40
11814 ± 2262
10698 ± 1750
1.3E4 ± 2.5E3
1.8E4 ± 4.5E3
86.20 ± 8.04
91.96 ± 9.90
3740 ± 612.6
3778 ± 629.7
1.43 ± 0.12
1.48 ± 0.11
17.19 ± 2.18
17.18 ± 2.18
1992 ± 109.9
2042 ± 143.4
76.64 ± 6.83
91.34 ± 9.04
3859 ± 510.9
3916 ± 492.0
80.83 ± 13.56
103.4 ± 16.96
1991 ± 306.9
2094 ± 318.0
431.1 ± 51.99
532.3 ± 67.78
1483 ± 115.3
1584 ± 81.05
116.8 ± 30.29
101.8 ± 25.72
4639 ± 795.6
4654 ± 825.2
A number of research groups have reported amelioration of experimental allergic and autoimmune diseases through the establishment of oral tolerance [40–42]. Most of these studies employed well defined solitary antigens such as OVA in order to isolate the desired response without excessive background interference. Our current work differed from previous approaches in that it employed a complex allergen mixture containing the defatted whole body extract of German cockroaches. This mixture contains the complete corporeal proteins of the cockroach, as well as a host of bioactive enzymes and the innate immune stimulants chitin and LPS. These experiments represent a broader approach to allergen desensitization. Namely, this study sought to tolerize experimental animals to the whole host of cockroach derived products which human subjects are likely to encounter in urban environments.
It has previously been reported that oral exposure to OVA in the drinking water of experimental mice significantly decreased the airways hyperreactivity to methacholine and the production of Th2 cytokines such as IL-5 and IL-13 . Our research obtained similar results to this previous study since the Penh of experimental mice fed with CRA was significantly lower than that of PBS fed mice. This indicated that the allergen fed mice were in a superior state of respiratory health as a result of the prior, gastric exposure to the putative antigen(s).
As mentioned previously, other research groups, using isolated allergens have been able to induce significant declines in Th2 cytokines following antigen tolerization. Interestingly, we saw no differences in any of the cytokines and chemokines traditionally measured in allergic pulmonary inflammation. We therefore had to seek other explanations for the improved respiratory health we observed in our allergen tolerized mice. Other groups have shown decreases in inflammatory cell infiltrate following oral allergen desensitization [44, 45]. In our studies we observed significantly diminished eosinophil recruitment to the lung airspaces with no differences in the BAL levels of other inflammatory cells. However, circulating blood eosinophils did not differ between the experimental groups. That an equivalent number of eosinophils were recruited into the blood in the CRA-fed and PBS-fed animals is not surprising considering that BAL and LH levels of chemotactic agents for these cells were equivalent between groups. This suggests that the mechanism for decreased eosinophil infiltration into the lung air spaces is regulated at the level of organ itself, potentially during adhesion/transmigration. In addition EPO activity was also significantly decreased in the CRA fed mice. Taken together, these data suggest that the recruitment of eosinophils has been inhibited to both the bronchoalveolar space and the lung parenchyma as a whole.
Although the numbers of eosinophils in the lung were decreased in the CRA fed mice, the levels of chemotactic agents were not significantly different between the two groups. Eotaxin 1 and 2 are as their name suggests potent chemo attractants for eosinophils yet their concentrations were not significantly decreased in the CRA fed groups [46, 47]. IL-4 and IL-5 are also known eosinophil chemotaxins and activators, but the levels of these cytokines were equivalent between the experimental groups [48, 49]. In addition, IL-13 which has been identified as necessary for the entrance of eosinophils into the lung did not differ between the groups [50, 51].
Having exhausted the traditional mediators of eosinophil recruitment we decided to probe IL-10 levels. This cytokine has been shown to inhibit the recruitment of eosinophils and alternately improve or aggravate airways hyperreactivity [38, 39, 52]. IL-10 levels were significantly elevated in the lung homogenate supernatant of the CRA fed mice with the means differing by approximately 1000 pg/mL. This represents a 20% increase in IL-10 production in the allergen fed mice. Whether this is a biologically significant difference is uncertain. IL-10 is known promote the development of oral tolerance, but the elevated levels seen after the final challenge are not directly related to the tolerization period which took place 24 days prior to the final challenge [53, 54]. This supposition is supported in that the OVA tolerized mice did not differ in lung homogenate IL-10 levels as would be expected if a gastric tolerizing event was responsible for this late cytokine production (data not shown). Thus it seems likely that the post challenge increase in IL-10 is a separate event related to the pulmonary allergen exposure. Interestingly, the secretion of this immunomodulatory cytokine seems limited to the pulmonary environment as serum levels of IL-10 were below detection limit.
In conclusion, oral exposure to cockroach allergen prior to pulmonary sensitization and challenge leads to significantly improved respiratory health in experimental mice. This improvement is due to reduced eosinophil recruitment into the air spaces and lung parenchyma. The inhibition of eosinophil recruitment may be related to increased production of IL-10 in the lung. Finally, this research suggests that oral tolerization to a complex environmental allergen is a viable option for desensitization in allergic airways disease.
This research indicates that oral tolerization is a valid means to reduce pulmonary inflammation in a mouse model of allergic asthma. Oral tolerization presents an attractive therapeutic option for human asthmatics in that it addresses the primary cause of allergic asthma exacerbations rather than simply blunting the symptoms. In addition oral tolerization offers significant advantages over other desensitization procedures (epidermal injections) in that there is a much lower risk of anaphylaxis and treatments may be self-administered after an initial observation period.
The lead author would like to thank the Boston University School of Medicine Immunology Training Grant Program for instruction and funding.
Research funded by NIEHS grant number: 5R01ES013538-04 and NIH training grant number: 2T32AI007309-21A1
- Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic obstructive pulmonary disease surveillance--United States, 1971–2000. MMWR Surveill Summ 2002,51(6):1–16.Google Scholar
- National Heart LaBI: Morbidity and Mortality: 2007 Chart Book On Cardiovascular, Lung and Blood Diseases. 2007.Google Scholar
- Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, Mitchell H, McNiff-Mortimer K, Lynn H, Ownby D, et al.: The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997,336(19):1356–1363.View ArticlePubMedGoogle Scholar
- Campbell EM, Kunkel SL, Strieter RM, Lukacs NW: Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. J Immunol 1998,161(12):7047–7053.PubMedGoogle Scholar
- McKinley L, Kim J, Bolgos GL, Siddiqui J, Remick DG: Reproducibility of a novel model of murine asthma-like pulmonary inflammation. Clin Exp Immunol 2004,136(2):224–231.View ArticlePubMedPubMed CentralGoogle Scholar
- National Heart La BI: Guidelines for the diagnosis and management of asthma. 2007.Google Scholar
- Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med 1995,332(13):868–875.View ArticlePubMedGoogle Scholar
- Becker , et al.: Immunotherapy: Rationale for allergen immunotherapy. Canadian Medical Association Journal 2005, s46-s50.Google Scholar
- Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004,351(7):668–674.View ArticlePubMedGoogle Scholar
- Frew AJ: Sublingual immunotherapy. N Engl J Med 2008,358(21):2259–2264.View ArticlePubMedGoogle Scholar
- Giampiero : Sublingual Desensitization: A new approach to the latex allergy problem. Anesthesia and Analgesia 2002, 60:956–960.Google Scholar
- Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M: Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995,182(5):1527–1536.View ArticlePubMedGoogle Scholar
- Kim J, McKinley L, Siddiqui J, Bolgos GL, Remick DG: Prevention and reversal of pulmonary inflammation and airway hyperresponsiveness by dexamethasone treatment in a murine model of asthma induced by house dust. Am J Physiol Lung Cell Mol Physiol 2004,287(3):L503–509.View ArticlePubMedGoogle Scholar
- Mckinley L, Kim J, Bolgos GL, Siddiqui J, Remick DG: Reproducibility of a novel model of murine asthma-like pulmonary inflammation. Clinical and Experimental Immunology 2004,136(2):224–231.View ArticlePubMedPubMed CentralGoogle Scholar
- Nemzek JA, Siddiqui J, Remick DG: Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods 2001,255(1–2):149–157.View ArticlePubMedGoogle Scholar
- Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, et al.: Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nature Medicine 2008,14(2):199–204.View ArticlePubMedPubMed CentralGoogle Scholar
- Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. American Journal of Respiratory and Critical Care Medicine 1997,156(3):766–775.View ArticlePubMedGoogle Scholar
- Lomask M: Further exploration of the Penh parameter. Experimental and Toxicologic Pathology 2006, 57:13–20.View ArticlePubMedGoogle Scholar
- Adler A, Cieslewicz G, Irvin CG: Unrestrained plethysmography is an unreliable measure of airway responsiveness in BALB/c and C57BL/6 mice. Journal of Applied Physiology 2004,97(1):286–292.View ArticlePubMedGoogle Scholar
- Lundblad LKA, Irvin CG, Adler A, Bates JHT: A reevaluation of the validity of unrestrained plethysmography in mice. Journal of Applied Physiology 2002,93(4):1198–1207.View ArticlePubMedGoogle Scholar
- Mitzner W: Why can't mice just learn to pant? Journal of Applied Physiology 2008,105(2):402–402.View ArticlePubMedGoogle Scholar
- de Hennezel L, Debarre S, Ramisse F, Delamanche S, Harf A, Alonso JM, Calvet JH: Plethysmography for the assessment of pneumococcal pneumonia and passive immunotherapy in a mouse model. Eur Respir J 2001,17(1):94–99.View ArticlePubMedGoogle Scholar
- Hemmila MR, Kim J, Sun JM, Cannon J, Arbabi S, Minter RM, Su GL, Remick DG, Wang SC: Gene therapy with lipopolysaccharide binding protein for gram-negative pneumonia: respiratory physiology. J Trauma 2006,61(3):598–605. discussion 605–596View ArticlePubMedGoogle Scholar
- Mansell AL, Walders N, Wamboldt MZ, Carter R, Steele DW, Devin JA, Monica TH, Miller AL, Wamboldt FS: Effect of body mass index on response to methacholine bronchial provocation in healthy and asthmatic adolescents. Pediatr Pulmonol 2006,41(5):434–440.View ArticlePubMedGoogle Scholar
- Baydur A, Wilkinson L, Mehdian R, Bains B, Milic-Emili J: Extrathoracic expiratory flow limitation in obesity and obstructive and restrictive disorders: effects of increasing negative expiratory pressure. Chest 2004,125(1):98–105.View ArticlePubMedGoogle Scholar
- Hoshino Y, Ayuse T, Kurata S, Schneider H, Kirkness JP, Patil SP, Schwartz AR, Oi K: The compensatory responses to upper airway obstruction in normal subjects under propofol anesthesia. Respir Physiol Neurobiol 2009,166(1):24–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Rudolf CD: Rudolf's Pediatrics. McGraw Hill; 2002:277.Google Scholar
- Tantucci C, Ellaffi M, Duguet A, Zelter M, Similowski T, Derenne JP, Milic-Emili J: Dynamic hyperinflation and flow limitation during methacholine-induced bronchoconstriction in asthma. Eur Respir J 1999,14(2):295–301.View ArticlePubMedGoogle Scholar
- Cascao R, Rosario HS, Fonseca JE: Neutrophils: warriors and commanders in immune mediated inflammatory diseases. Acta Reumatol Port 2009,34(2B):313–326.PubMedGoogle Scholar
- Szczepaniak W, Wolanczyk-Medrala A, Medrala W: Modern views on the role of neutrophil in the pathogenesis of bronchial asthma. Pol Merkur Lekarski 2003,14(79):55–58.PubMedGoogle Scholar
- Peters-Golden M: The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol 2004,31(1):3–7.View ArticlePubMedGoogle Scholar
- Afshar R, Medoff BD, Luster AD: Allergic asthma: a tale of many T cells. Clin Exp Allergy 2008,38(12):1847–1857.View ArticlePubMedGoogle Scholar
- Calvani M, Giorgio V, Miceli Sopo S: Specific oral tolerance induction for food. A systematic review. Eur Ann Allergy Clin Immunol 42(1):11–19.Google Scholar
- Baraldo S, Lokar Oliani K, Turato G, Zuin R, Saetta M: The Role of Lymphocytes in the Pathogenesis of Asthma and COPD. Curr Med Chem 2007,14(21):2250–2256.View ArticlePubMedGoogle Scholar
- Busse WW, Sedgwick JB: Eosinophils in asthma. Ann Allergy 1992,68(3):286–290.PubMedGoogle Scholar
- Conroy DM, Williams TJ: Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001,2(3):150–156.View ArticlePubMedPubMed CentralGoogle Scholar
- Fahy JV: Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009,6(3):256–259.View ArticlePubMedGoogle Scholar
- Nakagome K, Dohi M, Okunishi K, Komagata Y, Nagatani K, Tanaka R, Miyazaki J, Yamamoto K: In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J Immunol 2005,174(11):6955–6966.View ArticlePubMedGoogle Scholar
- van Scott MR, Justice JP, Bradfield JF, Enright E, Sigounas A, Sur S: IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice. Am J Physiol Lung Cell Mol Physiol 2000,278(4):L667–674.PubMedGoogle Scholar
- Shin JH, Kang JM, Kim SW, Cho JH, Park YJ: Effect of oral tolerance in a mouse model of allergic rhinitis. Otolaryngol Head Neck Surg 142(3):370–375.Google Scholar
- Russo M, Nahori MA, Lefort J, Gomes E, de Castro Keller A, Rodriguez D, Ribeiro OG, Adriouch S, Gallois V, de Faria AM, et al.: Suppression of asthma-like responses in different mouse strains by oral tolerance. Am J Respir Cell Mol Biol 2001,24(5):518–526.View ArticlePubMedGoogle Scholar
- Park KS, Park MJ, Cho ML, Kwok SK, Ju JH, Ko HJ, Park SH, Kim HY: Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol 2009,19(6):581–589.View ArticlePubMedGoogle Scholar
- Keller AC, Mucida D, Gomes E, Faquim-Mauro E, Faria AM, Rodriguez D, Russo M: Hierarchical suppression of asthma-like responses by mucosal tolerance. J Allergy Clin Immunol 2006,117(2):283–290.View ArticlePubMedGoogle Scholar
- Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ, Curotto de Lafaille MA: Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 2005,115(7):1923–1933.View ArticlePubMedPubMed CentralGoogle Scholar
- Faria AM, Weiner HL: Oral tolerance. Immunol Rev 2005, 206:232–259.View ArticlePubMedGoogle Scholar
- Bandeira-Melo C, Herbst A, Weller PF: Eotaxins. Contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 2001,24(6):653–657.View ArticlePubMedGoogle Scholar
- Rankin SM, Conroy DM, Williams TJ: Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000,6(1):20–27.View ArticlePubMedGoogle Scholar
- Dubois GR, Bruijnzeel PL: IL-4-induced migration of eosinophils in allergic inflammation. Ann N Y Acad Sci 1994, 725:268–273.View ArticlePubMedGoogle Scholar
- Kouro T, Takatsu K: IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009,21(12):1303–1309.View ArticlePubMedGoogle Scholar
- Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME: IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001,108(4):594–601.View ArticlePubMedGoogle Scholar
- Castilow EM, Meyerholz DK, Varga SM: IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol 2008,180(4):2376–2384.View ArticlePubMedGoogle Scholar
- Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001,2(8):725–731.View ArticlePubMedGoogle Scholar
- Battaglia M, Gianfrani C, Gregori S, Roncarolo MG: IL-10-producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci 2004, 1029:142–153.View ArticlePubMedGoogle Scholar
- Safadi R, Alvarez CE, Ohta M, Brimnes J, Kraus T, Mehal W, Bromberg J, Mayer L, Friedman SL: Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10. J Immunol 2005,175(6):3577–3583.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.